Nabriva Completes Enrollment in Phase 3 Trial Testing Lefamulin for Community-Acquired Bacterial Pneumonia
Austria’s Nabriva Therapeutics has finished enrolling patients for its first Phase 3 clinical trial evaluating lefamulin treatment against community-acquired bacterial pneumonia (CABP). The most common type of pneumonia, CABP afflicts more than five ... Read more